MedTrace Logo

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

NCT05628610 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-08-13

No results posted yet for this study

Summary

To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis

Conditions

  • Esophageal Cancer

Interventions

DRUG

Tislelizumab

200mg d1, Q3W

RADIATION

Radiation

Radiotherapy dose: 5,000 c G y / 30f

DRUG

Paclitaxel

Paclitaxel: 150mg / m2 ,d1, q3w

DRUG

Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs

cisplatin, carboplatin, naidaplatin and other platinum drugs

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-09-30
Completion
2027-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05628610 on ClinicalTrials.gov